The Pharmaceutical Journal
Vol 272 No 7305 p794
26 June 2004

This article
Reprint   Photocopy

  Acrobat Reader

News summary

NICE to examine drug misuse treatments

Clinical guidelines on the treatment of drug misusers, and assessments of methadone and buprenorphine as opiate substitutes, and the use of naltrexone to prevent relapse are to be produced by the National Institute for Clinical Excellence.

The Department of Health and the Welsh Assembly Government have also asked NICE to draw up advice for the NHS in England and Wales on methylphenidate and other interventions for the treatment of attention-deficit/hyperactivity disorder, the care and management of osteoarthritis and management of faecal incontinence.

Other technology appraisals to be produced as part of NICE’s 10th work programme include inhaled insulin for the management of type 1 and type 2 diabetes, various drug therapies for prostate cancer, head and neck cancer, mesothelioma and colon cancer; therapies for age-related macular degeneration and for multiple sclerosis, rheumatoid arthritis, osteoporosis; and corticosteroids for asthma.